Previous study report XCL1/GPC3 fusion gene immunization generates potent antitumour cellular immunity and enhances Anti–PD-1 efficacy [30], but our study further confirm targeting GPC3 can sensitize the PD-1 blockage therapy in GC. This evidence concerns the gene XCL1 and gastric cancer.